Lazaris A C, Theodoropoulos G E, Anastassopoulos P, Nakopoulou L, Panoussopoulos D, Papadimitriou K
University Surgical Department, Hippokration General Hospital, Athens, Greece.
Histol Histopathol. 1995 Jul;10(3):661-8.
Mutant p53 tumour suppressor gene and c-erbB-2 proto-oncogene are involved in human carcinogenesis, and their protein product detection in human malignancies might influence the evolution of many neoplasms. Our aim was to estimate their association with histopathological and clinical parameters of prognostic value in colorectal cancer. An immunohistochemical assay was undertaken in formalin-fixed sections from tissue specimens of 60 colorectal carcinomas. Nuclear p53 expression was detected in 46.6%, while membranic c-erbB-2 positivity was noticed in 35% of the examined cases. P53 positivity rate significantly correlated with poor differentiation (p < 0.001), high mitotic activity (p < 0.0001), tumour stage (p < 0.001) and 5-year overall survival period (p < 0.01). C-erbB-2 positivity incidence significantly correlated with advanced Dukes' stage (p < 0.001) and high mitotic activity (p < 0.05). Significant association between p53 and c-erbB-2 immunostaining was observed (p < 0.05) and p53/c-erbB-2 co-expression was related to poor differentiation (p < 0.001), high mitotic activity (p < 0.001), advanced Dukes' stage (p < 0.001), tumour aneuploidy (p < 0.05) and worse overall survival (p < 0.05). P53 and c-erbB-2 immunohistochemical detection in combination with known prognostic indicators may be a useful future tool in determining colorectal cancer prognosis and subsequently in deciding on optimal postoperative treatments.
突变型p53肿瘤抑制基因和c-erbB-2原癌基因参与人类致癌过程，在人类恶性肿瘤中检测它们的蛋白质产物可能会影响许多肿瘤的进展。我们的目的是评估它们与结直肠癌预后价值的组织病理学和临床参数之间的关联。对60例结直肠癌组织标本的福尔马林固定切片进行了免疫组织化学检测。在46.6%的病例中检测到核p53表达，而在35%的受检病例中发现膜c-erbB-2阳性。p53阳性率与低分化（p<0.001）、高有丝分裂活性（p<0.0001）、肿瘤分期（p<0.001）和5年总生存期（p<0.01）显著相关。c-erbB-2阳性发生率与晚期Dukes分期（p<0.001）和高有丝分裂活性（p<0.05）显著相关。观察到p53和c-erbB-2免疫染色之间存在显著关联（p<0.05），p53/c-erbB-2共表达与低分化（p<0.001）、高有丝分裂活性（p<0.001）、晚期Dukes分期（p<0.001）、肿瘤非整倍体（p<0.05）和更差的总生存期（p<0.05）相关。将p53和c-erbB-2免疫组织化学检测与已知的预后指标相结合，可能是未来确定结直肠癌预后并随后决定最佳术后治疗的有用工具。
